These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Generation prozac.
    Author: Grodeck B.
    Journal: Posit Aware; 1995; ():18-9. PubMed ID: 11362374.
    Abstract:
    About forty million Americans will experience a major depressive illness sometime during their lives. However, many will not seek treatment because of the social stigma attached to the disorder--depression is a sign of weakness or failure. For those that do seek treatment, many alternatives are available. The first generation of antidepressants, dubbed tricyclics (TCAs), provide relief from depression, but produce severe side effects. Monoamine oxidase inhibitors (MAOIs) allow more norepinephrine, dopamine, and serotonin to be produced--neurotransmitters linked to moods and sleep. They also exhibit many side effects. The newest drugs, selective serotonin reuptake inhibitors (SSRIs), relieve depression similar to the TCAs and MAOIs, but have a lower rate of unpleasant side effects. Prozac, within the SSRI family, is the most popular and most studied drug for the treatment of depression. Discovered by pharmaceutical company Eli Lilly and approved by the Food and Drug Administration (FDA) in 1987, prozac has been shown to work against obsessive-compulsive disorder, suicidal thoughts, and aggressive behavior--all of which can be symptoms of depression.
    [Abstract] [Full Text] [Related] [New Search]